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licenses/by/4.0/).Abstract Purpose: No studies extensively compared the young adults (YA, 18e39 years),
middle-aged (40e69 years), and elderly (70 years) population with primary high-grade ex-
tremity soft tissue sarcoma (eSTS). This study aimed to determine whether the known effect
of age on overall survival (OS) and disease progression can be explained by differences in
tumour characteristics and treatment protocol among the YA, middle-aged and elderly pop-
ulation in patients with primary high-grade eSTS treated with curative intent.
Methods: In this retrospective multicentre study, inclusion criteria were patients with primary
high-grade eSTS of 18 years and older, surgically treated with curative intent between 2000
and 2016. Cox proportional hazard models and a multistate model were used to determine
the association of age on OS and disease progression.
Results: A total of 6260 patients were included in this study. YA presented more often after
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I. Acem et al. / European Journal of Cancer 141 (2020) 128e136 129tumours. Elderly patients presented more often with grade III and larger (10 cm) tumours.
After adjustment for the imbalance in tumour and treatment characteristics the hazard ratio
for OS of the middle-aged population is 1.47 (95% confidence interval [CI]: 1.23e1.76) and
3.13 (95% CI: 2.59e3.78) in the elderly population, compared with YA.
Discussion: The effect of age on OS could only partially be explained by the imbalance in the
tumour characteristics and treatment variables. The threefold higher risk of elderly could, at
least partially, be explained by a higher other-cause mortality. The results might also be ex-
plained by a different tumour behaviour or suboptimal treatment in elderly compared with
the younger population.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Soft tissue sarcomas (STSs) are a group of rare hetero-
geneous tumours of mesenchymal origin with various
histologic and clinical features. The estimated incidence
of STS is less than 4.7 per 100,000 persons in Northern
Europe per year [1]. STSs may occur in all age groups,
with a relatively high incidence in patients younger than
40 years compared with other malignancies [1,2]. STS
represent approximately 1e2% of all adult malignancies
(2, 3) and 7e8% of all malignancies in adolescents and
young adults (AYAs) [3,4].
In the past, clinical trialsmainly focused on themiddle-
aged population, in which STS is the most prevalent [3],
whereas the AYAs and elderly population remained un-
derrepresented in these trials [5,6]. The lack of enrolment
in clinical trials of theAYAs and elderly population limits
our knowledge of tumour behaviour and effectiveness of
STS management in these populations.
Several studies have shown relative lack of improve-
ment in clinical outcomes in the AYA population
compared with their older and younger counterparts (4,
7) and poorer disease-specific survival of the elderly
patients compared to the younger counterparts [8]. With
the increasing referrals for treatment of elderly patients
with STS, as well as the lack of improvement in the
AYA population, further evaluation of factors influ-
encing outcome for the different age groups might help
in the decision-making regarding treatment strategies
for the different patient groups [4,7,9,10].
Therefore, the primary aim of this study is to evaluate
differences in overall survival (OS) and disease progres-
sion among age groups of patients with a primary high-
grade eSTS treated with a curative intent. The secondary
aim is to determine whether potential differences in
outcome can be explained by differences in tumour and
treatment characteristics among the different age groups.2. Methods
2.1. Study design and population
This is a retrospective multicentre study of surgically
treated patients with primary high-grade eSTS. Localinstitutional ethics board approval was obtained before
the study. Patients were identified from 21 participating
specialized sarcoma centres or registries (Appendix A).
All patients with primary high-grade (FNCLCC II/
III) eSTS of 18 years and older that were surgically
treated with curative intent between 2000 and 2016 with
correctly registered time-to-events were included. Pa-
tients undergoing re-excision after unplanned sarcoma
excision were also included. Exclusion criteria were:
- presentation with local recurrence (LR) or distant metas-
tasis (DM)
- intermediate malignancy tumours, Kaposi and paediatric
sarcomas
- patients receiving (neo)adjuvant treatment other than
radiotherapy (RTX) or chemotherapy (CTX) (e.g. isolated
limb perfusion)
- patients who died or were censored at the day of definitive
surgery
- patients of whom age or time-to-event data were missing.
2.2. Variables
Patient information, tumour characteristics, treatment-
related variables and survival data were obtained from
medical records or sarcoma registries. Age was deter-
mined as age at time of surgery. Patients were catego-
rized into three age groups (YA: 18e39, middle-aged:
40e69, elderly: 70þ). Size was measured as the
maximum diameter of tumour mass on imaging-
techniques or based on pathological report. The
Fédération Nationale des Centres de Lutte Contre le
Cancer (FNCLCC) grading-system was used for tumour
grading. A tumour partially or entirely deep to the
investing fascia was classified as deep. Histological
subtypes were retrieved from pathology reports and
were classified into 7 categories according to the World
Health Organization classification [11]: leiomyosarcoma
(LMS), liposarcoma (LPS), myxofibrosarcoma (MF),
undifferentiated pleomorphic sarcoma and (pleomor-
phic) STS not-otherwise-specified (UPS/NOS), malig-
nant peripheral nerve sheath tumour (MPNST),
synovial sarcoma (SS) and other. The ‘other’-category
included angiosarcoma, adult rhabdomyosarcoma and










Fig. 1. Disease progression of eSTS in a multistate model along with
number of patients moving from one state to another. The states are
indicated by blocks and the transitions are indicated by arrows. )
Patients with synchronous relapse (LR þ DM) move to the DM-
state. If a patient first develops a DM and afterwards a LR, the
patient will remain in the DM-state. ANED Z alive no evidence
of disease, LR Z local recurrence, DM Z distant metastasis.
I. Acem et al. / European Journal of Cancer 141 (2020) 128e136130A ‘whoops’-surgery was defined as a surgical procedure
in which the mass was assumed to be benign but final
pathologic diagnosis after surgery showed an STS.
Surgical margin was classified as R0 (negative, defined
as no ink on tumour) or R1-2 (microscopically/macro-
scopically positive). No central pathology review for the
diagnosis and surgical margin was performed in this
study. Owing to the retrospective and multicentre nature
of this study, it was not possible to centrally review 6260
eSTS cases. Because only expert centres were included in
this study, we believe central review would not signifi-
cantly improve the article to warrant such an effort. All
centres generally adhered to the ESMO-guidelines for
diagnosis, treatment and follow-up [12].
LR was defined as the first radiological evidence of
malignant recurrence at or near the primary tumour
bed. DM was defined as the first radiological or path-
ological evidence of recurrence at any other side outside
the primary tumour bed. For the date of LR and DM,
the date of tissue biopsy was used if the diagnosis was
pathologically confirmed, otherwise the date of radio-
logical examination was used.
End points of the study were OS, LR and DM.
2.3. Statistical analysis
All statistical analyses were performed in the statistical
program R (version 3.6.3) [13]. Patient demographics
and baseline characteristics were described with pro-
portions for categorical variables and means with stan-
dard deviations or medians with interquartile ranges
(IQRs). Differences in categorical variables were tested
with the chi-square test or Fisher’s exact test.
Bonferroni-correction for differences in tumour and
treatment variables between the age groups was used to
account for multiple testing.
OS was defined as the time interval between definitive
surgery and date of death or date of last follow-up.
Time-to-LR and time-to-DM was defined as the time
interval between definitive surgery and date of LR or
DM, respectively, or date of last follow-up. Median
survival was computed with the reversed Kaplan-Meier
estimator. Kaplan-Meier plots for OS and cumulative
incidence of LR (CILR) and cumulative incidence of
DM (CIDM) plots were constructed to compare the
YA, middle-aged and elderly age groups. The CILR and
CIDM were estimated using competing risk analyses,
with death as competing event. Differences in time-to-
event outcomes were evaluated with the log-rank test or
the Peto-Wilcoxon test if the proportional hazard (PH)
assumption was violated. Missing values were imputed
for the Cox PH models using multiple imputation
(m Z 20). Pooled estimates were computed using
Rubin’s rules.
A multistate model was built to assess the association
between age and disease progression. A multistate model
is an extension of competing risk analyses, in whichtransitions to and from intermediate events are
modelled [14]. Fig. 1 depicts the multistate model used in
this study. Every patient starts in the initial state after
definitive surgery, alive with no evidence of disease
(ANED). A patient stays in this state until disease pro-
gression, death or censoring. If a patient first develops a
LR and afterwards a DM, the patient will move from
ANED toLR toDM. If a patient first develops aDMand
afterwards a LR, the patient will move from ANED to
DM and remains in DM. If a patient is diagnosed with a
LR and DM simultaneously (synchronous relapse) the
patient will move directly to the DM-state.
Multivariable Cox PH models were used to estimate
the effect of age on OS and for each transition. The
models were adjusted for tumour and treatment charac-
teristics. The tumour characteristics were histology,
grade, size, depth and tumour site. The treatment char-
acteristics were surgical margin, radiotherapy and
chemotherapy. We assessed the PH-assumption visually
using the Schoenfeld-residuals. We used state occupancy
plots to visualize the probability of being in a state at
different time point after surgery for the three age groups.
P-values 0.05 were considered statistically signifi-
cant. Results from the Cox PH models were described in
hazard ratios (HRs) with corresponding 95% confidence
intervals (CIs). All statistical tests were two-sided. The
packages ‘mstate’, ‘mcprsk’ and ‘survival’ were used for
the multistate model and survival analyses, and the
package ‘mice’ was used for multiple imputations.
3. Results
3.1. Patient population
A total of 6268 patients were eligible for this study. Two
patients due to missing age, three patients due to missing
time-to-event data and three patients without follow-up
were excluded, resulting in 6260 patients that were
I. Acem et al. / European Journal of Cancer 141 (2020) 128e136 131included (Fig. 2). The ages ranged between 18 and 100
years (median, IQR: 63, 49e74). The population was
categorized into three age groups: the YA (n Z 841,
13.4%), the middle-aged (n Z 3217; 51.4%) and the
elderly population (n Z 2202; 35.2%) (Table 1). The
female:male ratio in the total population was 1:1.24. The
median follow-up time was 49.4 months (95% CI:
47.1e52.3).
3.2. Differences in tumour characteristics
YA presented more often after ‘whoops’-surgery or for
reresection due to residual disease compared with both
the middle-aged and elderly population. Also, YA had
significantly more deep-seated tumours compared with
the middle-aged, and elderly population, while elderly
presented more often with grade III and large (10 cm)
tumours compared with the YA and middle-aged
population.
SS, MPNST and LPS were significantly more often
diagnosed in YA compared with the middle-aged and
elderly population, whereas UPS and NOS were diag-
nosed more often in elderly compared with the YA and
middle-aged population. LMS and MF were more
frequent in the middle-aged and elderly population
compared with YA. No significant difference was found
between the middle-aged and elderly population for
LMS and MF (Table 1). Fig. 3 describes the age dis-
tribution for the main histologic subtypes.
3.3. Differences in treatment
Elderly had significantly more R1-R2 resections
compared with the YA and middle-aged population.
RTX and CTX were more often offered in the YA and
middle-aged population compared with elderly. In
addition, there was a significant difference in CTX use
between the YA and middle-aged population.6,268 pa ents eligible
6,260 pa ents included 
in analysis
Excluded (n=8)
• Missing age (n=2)
• Missing me-to-
event data (n=3)










Fig. 2. Consort diagram for patients included in the study. YA Z
young adults.3.4. Differences in outcome
There was a significant difference among the age groups
for all oncological outcomes (Fig. 4). The 5-year OS in
the YA, middle-aged and elderly population, is 78.4%
(95% CI: 75.0e81.9), 70.3% (95% CI: 68.4e72.3) and
50.0% (95% CI: 47.3e52.9), respectively (Table 2).
Age was significantly associated with OS in the uni-
variate model (Fig. 4a). After adjustment for the pre-
sentation and treatment variables, the association
between age and OS decreased but remained significant
(HR middle-aged: 1.47 (95% CI: 1.23e1.76), HR
elderly: 3.13 (95% CI: 2.59e3.78), YA as reference)
(Table 3).
Age demonstrated a significant effect on the cause-
specific hazard of LR (Fig. 4b). The difference in the
cause-specific hazard of LR between the YA and
middle-aged population could entirely be explained by
the imbalance in tumour and treatment characteristics
(HR middle-aged: 1.38 (95% CI: 0.976e1.94), YA as
reference). Difference in the cause-specific hazard of LR
between the YA and elderly population could partially
be explained by the imbalance in tumour and treatment
characteristics (HR elderly: 2.19 (95% CI: 1.52e3.16),
YA as reference) (Table 3, transition 1). In addition, age
demonstrated a significant effect on the cause-specific
hazard of DM (Fig. 4c). The imbalance in tumour and
treatment characteristics does not seem to explain the
difference in the cause-specific hazard of DM among the
age groups (HR middle-aged: 1.28 (95% CI: 1.08e1.51),
HR elderly: 1.26 (95% CI: 1.04e1.52), YA as reference)
(Table 3, transition 2). HRs for the elderly were the
highest for transition 3 (ANED / Death) and 5
(LR/Death) (Table 3). Cumulative incidence plots for
LR and DM stratified by age group and histology are
depicted in appendix C.3.5. State occupancy probabilities
The probability of occupying the LR state is similar for
each age group over time. The probability of occupying
the DM-state in the first year after definitive surgery is
the highest in elderly patients compared with the YA
and middle-aged population. The probability of occu-
pying the DM decreases after a year because of people
moving to the death state (Fig. 5).4. Discussion
This study showed significant differences among the
YA, middle-aged and elderly population in tumour
characteristics, treatment strategies and all oncological
outcomes. The differences in OS among the age groups
could partially be explained by the imbalance in
tumour and treatment characteristics. The difference in
LR rates between the YA and middle-aged could
Table 1










Gender Male 3466 (55.4) 464 (55.2) 1815 (56.4) 1187 (53.9)
Female 2793 (44.6) 377 (44.8) 1401 (43.6) 1015 (46.1) 0.182
Missing 1 1
Histology LMS 657 (10.5) 50 (5.95) 336 (10.5) 271 (12.3)
LPS 1002 (16.0) 191 (22.7) 569 (17.7) 242 (11.0)
MF 1095 (17.5) 42 (4.99) 599 (18.6) 454 (20.6)
UPS and NOS 1948 (31.1) 96 (11.4) 959 (29.8) 893 (40.6)
MPNST 353 (5.64) 98 (11.7) 186 (5.79) 69 (3.14)
SS 570 (9.11) 267 (31.7) 254 (7.90) 49 (2.22)
Other 631 (10.1) 97 (11.5) 312 (9.70) 222 (10.1) <0.001
Missing 4 2 2
Grade 2 1008 (24.6) 169 (29.2) 585 (27.3) 254 (18.4)
3 3096 (75.4) 410 (70.8) 1560 (72.7) 1126 (81.6) <0.001
High-grade (not further
specified)
2156 262 1072 822
Size <5 cm 1510 (24.9) 239 (29.7) 802 (25.8) 469 (21.9)
5e10 cm 2383 (39.3) 323 (40.2) 1199 (38.5) 861 (40.2)
10 cm 2165 (35.7) 242 (30.1) 1112 (35.7) 811 (37.9) <0.001
Missing 202 37 104 61
Depth Deep 3257 (55.8) 484 (61.4) 1699 (56.7) 1074 (52.3)
Superficial 2582 (44.2) 304 (38.6) 1297 (43.3) 981 (47.7) <0.001
Missing 421 53 221 147
Site Lower extremity 4750 (75.9) 647 (76.9) 2501 (77.8) 1602 (72.8)
Upper extremity 1509 (24.1) 194 (23.1) 715 (22.2) 600 (27.2) <0.001
Missing 1 1
Presentation Primary 3814 (78.8) 489 (73.2) 1928 (78.1) 1397 (82.0)
Whoops/residue 1028 (21.2) 179 (26.8) 542 (21.9) 307 (18.0) <0.001
Missing 1418 173 747 498
Type of surgery Limb sparing 5059 (93.9) 674 (95.1) 2590 (93.9) 1795 (93.4)
Amputation 330 (6.12) 35 (4.94) 169 (6.13) 126 (6.56) 0.306
Missing 871 132 458 281
Resection margin R0 5338 (87.9) 737 (89.8) 2769 (89.2) 1832 (85.4)
R1-R2 732 (12.1) 84 (10.2) 336 (10.8) 312 (14.6) <0.001
Missing 190 20 112 58
Radiotherapy No 3016 (48.2) 379 (45.1) 1460 (45.4) 1177 (53.5)
Yes 3239 (51.8) 461 (54.9) 1753 (54.6) 1025 (46.5) <0.001
Missing 5 1 4
Chemotherapy No 5240 (83.7) 593 (70.5) 2526 (78.5) 2121 (96.3)




No RT 3017 (48.6) 379 (45.4) 1459 (45.8) 1179 (53.8)
Adjuvant 2033 (32.7) 262 (31.4) 1062 (33.4) 709 (32.4)
Neoadjuvant 1135 (18.3) 190 (22.8) 647 (20.3) 298 (13.6)
Neo- and adjuvant 24 (0.387) 4 (0.479) 16 (0.503) 4 (0.183) <0.001
Missing 51 6 33 12
Chemotherapy
(detailed)
No CT 5241 (84.1) 593 (70.8) 2529 (79.1) 2119 (96.4)
Adjuvant 560 (8.98) 109 (13.0) 394 (12.3) 57 (2.59)
Neoadjuvant 190 (3.05) 64 (7.65) 119 (3.72) 7 (0.318)
Neo- and adjuvant 243 (3.90) 71 (8.48) 156 (4.88) 16 (0.728) <0.001
Missing 26 4 19 3
LMS, leiomyosarcoma; LPS, liposarcoma; MF, myxofibrosarcoma; NOS, not-otherwise-specified; UPS, undifferentiated pleomorphic sarcoma;
MPNST, malignant peripheral nerve sheath tumour; SS, synovial sarcoma.
a Global P value for differences in distribution across the age groups.
I. Acem et al. / European Journal of Cancer 141 (2020) 128e136132entirely be explained by the imbalance in these baseline
characteristics, but the difference between the YA and
elderly population could only partially be explained by
the imbalance. Differences in DM rates among the age
groups seem not to be explained by the imbalance in
tumour and treatment characteristics among the
groups.It is noteworthy that YA presented more often
after ‘whoops’-surgery. This is in line with the find-
ings of Younger et al. [15] which showed that AYA
were more vulnerable to incorrect diagnosis compared
with the elderly population. This could be explained
by the overall lower prevalence of malignant tumours







25 50 75 100
Age at time of surgery (years)
Fig. 3. Age distribution for histologic subtypes. Boxes represent the 25th 50th and 75th quartiles, end of horizontal bars represent 1.5 times
the interquartile range. Rhombus represents the mean. UPS, undifferentiated pleomorphic sarcoma; NOS, not-otherwise-specified; MF,
myxofibrosarcoma; LMS, leiomyosarcoma; LPS, liposarcoma; MPNST, malignant peripheral nerve sheath tumour; SS, synovial sarcoma.
I. Acem et al. / European Journal of Cancer 141 (2020) 128e136 133that STS can also affect YA. Another explanation for
the higher ‘whoops’ rates in the YA compared with
the elderly is that YA presented with smaller tumours,
which might mistakenly be considered benign more
frequently.
This study showed a higher overall mortality in the
elderly population compared with their younger counter-
parts, which is in accordance with previous studies [8,16].
In addition, elderly have a more than six and five times
higher risk of dying in the ANED and LR state, respec-
tively. Because OS was taken as an end point rather than
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Fig. 4. Kaplan-Meier curves. (A) Overall survival (log-rank: p < 0.001).
(C) Cumulative incidence of distant metastasis (Peto-Wilcoxon: p Z 0elderly obviously have a higher risk of dying of natural
causes. However, other studies have also shown an
increased sarcoma-specific mortality in the older
population [8,9,16,17].
The elderly presented with larger (10 cm) and more
grade III tumours compared with the YA and middle-
aged population. In addition, the variation in histolog-
ical subtypes in the elderly was different than in the
younger populations. Elderly were more frequently
diagnosed with UPS and NOS, which tend to be more
aggressive tumours [18]. All these tumour characteristics
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(B) Cumulative incidence of local recurrence (log-rank: p < 0.001).
.001).
Table 2
Oncological outcome stratified by age group.
Oncological outcome YA (95% CI) Middle-aged (95% CI) Elderly (95% CI)
Overall survival
2 year 91.1% (89.1e93.3) 86.2% (84.9e87.5) 71.8% (69.8e74.0)
5 year 78.4% (75.0e81.9) 70.3% (68.4e72.3) 50.0% (47.3e52.9)
10 year 66.7% (61.5e72.3) 58.4% (55.6e61.2) 23.7% (20.3e27.7)
Cumulative incidence of LR
1 year 2.91% (1.76e4.05) 4.67% (3.94e5.41) 6.33% (5.30e7.35)
2 year 5.90% (4.19e7.61) 7.34% (6.39e8.30) 11.2% (9.79e12.6)
5 year 9.45% (7.14e11.8) 10.7% (9.46e11.9) 16.6% (14.7e18.5)
Cumulative incidence of DM
1 year 10.8% (8.64e12.9) 17.0% (15.7e18.3) 17.6% (16.0e19.2)
2 year 20.8% (17.9e23.8) 25.6% (24.0e27.2) 24.1% (22.2e26.0)
5 year 28.8% (25.2e32.3) 34.2% (32.3e36.1) 29.4% (27.2e31.6)
Overall survival after first LR
1 year 79.8% (69.8e91.3) 66.7% (61.3e72.6) 59.9% (54.0e66.4)
2 year 54.0% (41.6e70.0) 49.1% (43.2e55.9) 45.5% (39.4e52.5)
5 year 41.5% (29.3e58.8) 32.0% (25.9e39.5) 22.7% (17.2e29.8)
Overall survival after first DM
1 year 70.1% (63.9e76.9) 59.6% (56.4e63.0) 35.9% (31.8e40.4)
2 year 42.4% (35.7e50.4) 37.1% (33.8e40.7) 15.8% (12.6e19.8)
5 year 21.7% (15.9e29.6) 16.8% (14.0e20.1) 6.28% (4.19e9.42)
YA Z young adults, LR Z local recurrence, DM Z distant metastasis, ANED Z alive with no evidence of disease.
I. Acem et al. / European Journal of Cancer 141 (2020) 128e136134in addition, elderly had more positive resection
margins. This might be due the fact that elderly pre-
sented more often with unresectable tumours, or that
surgeons chose to perform less extensive resections to
improve quality of life in the elderly. In addition, elderly
patients are less often offered radiation or chemo-
therapy, probably due to pre-existing comorbidities and
reduced physical and psychological reserves [9,10,19].
The lower rates of RTX use in the elderly might
explain the higher LR rates in this age group, as this
study showed a HR of 0.57 for the transition from
ANED / LR in those who received RTX. In addition,
RTX was associated with an improvement in OS (HR:
0.82). CTX was not associated with an improvement in
OS but was associated with the transition from
ANED / DM (HR: 1.4). This could probably be
explained by confounding by indication, as patients withTable 3
HRs of age for overall survival and all transitions in the multistate model.






Age HR (95% CI) HR (95% CI) HR (95% CI) HR (9




1.47 (1.23e1.76) 1.38 (0.976e1.94) 1.28 (1.08e1.51)
- Elderly 3.13 (2.59e3.78) 2.19 (1.52e3.16) 1.26 (1.04e1.52) 6.02 (
Adjusted for histology, grade, size, depth and tumour site, surgical margin
a For transition 3 (ANED / Death), the YA and middle-aged group
patients in this transition for these age groups.
b For transition 5 (LR / Death), we only adjusted for tumour character
Appendix B includes the full multistate model including het HRs of the adhigher risk of developing a DM are more likely to
receive CTX.
After adjustment for the imbalance in tumour and
treatment variables, the association between age and OS
decreases, suggesting that worse OS in the elderly may
only partially be explained by the imbalance of tumour
and treatment variables. However, it has been suggested
that elderly have a more aggressive tumour biology and
a weaker tumour-specific immune response [20,21],
which might be another explanation for decreased sur-
vival. This is supported by the finding that the proba-
bility of developing DM in the first year after surgery is
higher for the elderly compared with the younger
counterparts with the same tumour and treatment
characteristics. Besides elderly have a higher risk of
developing a DM, they also have a higher risk of dying








5% CI) HR (95% CI) HR (95% CI) HR (95% CI)
1 1 1
1.19 (0.660e2.14) 1.42 (0.508e3.94) 1.27 (1.04e1.55)
4.92e7.36) 0.742 (0.391e1.41) 4.58 (1.67e12.6) 2.25 (1.80e2.80)
, (neo)adjuvant radiotherapy and (neo)adjuvant chemotherapy.
were combined in one group due to the relatively small number of
istics due to the relatively small number of patients in this transition.
justed variables.

























































time in months since surgery
Fig. 5. State occupation probabilities for three patients with the same profile in each age group. Panel A: patient in the YA group with a
grade III, deep-seated, Malignant peripheral nerve sheaeth tumour of 10 cm of the lower limb treated with RT and R0-resection. Panel B:
patient in the middle-aged group with the same patient profile as A. Panel C: patient in the elderly group with the same patient profile as
A. The distance between two curves denotes the probability of being in a specific state at a specific time after surgery. YAZ young adults,
P Z alive no evidence of disease, D Z death, DM Z distant metastasis, LR Z local recurrence.
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population. We did not have any information about
the treatment regimens after disease progression, but a
potential explanation for the declined OS in elderly
could also be a less aggressive treatment approach in
this population.
This study found an increased risk of LR in the
elderly population compared with YA, in accordance
with previous reports [8,22], Also, an increased but less
evident risk of DM was found in the middle-aged and
elderly population compared with YA. After adjustment
for tumour and treatment characteristics, the difference
in cause-specific hazard of LR among the age groups
decreased. However, the association for the cause-
specific hazard of DM remained the same after adjust-
ment, suggesting that the imbalance in measured tumour
and treatment characteristics does not explain the dif-
ference in DM rate. These findings are in line with a
previous report of Biau et al. [22], which showed that the
effect of age on DM could hardly be explained by pre-
sentation and treatment variables. Yet, unmeasured or
not-fully modelled explanatory confounders could also,
at least partially, explain the remaining association.
However, our study included more than twice as many
patients compared with Biau et al. [22] which made it
possible to adjust for more variables without overfitting
the models.
4.1. Limitations and strengths
This study has several limitations due to its retrospective
design. First, missing data and patients lost to follow-up
were present in our data set, probably resulting in se-
lection bias due to selective lost to follow-up. We have
used multiple imputations to reduce the bias. Further-
more, the association among the age groups and clinical
outcome could be explained by other variables as we did
not include in our analysis, such as treatmentcharacteristics of progressive disease, resulting in resid-
ual confounding. In addition, we combined patients
with R1 and R2 resections in one group, as more
detailed information about surgical margins was not
available in all centres. Finally, we were unable to assess
the disease-specific survival which would provide more
insight into the influence of tumour and treatment
characteristics on the effect of age. Nevertheless, to our
knowledge, this is the largest multicentre study to date
examining age-related differences in oncological
outcome for patients with primary high-grade eSTS
surgically treated with curative intent.5. Conclusion
In this large multicentre study, we have observed a sig-
nificant decrease in OS and increase in LR and DM rate
with increasing age. This can only partially be explained
by differences in tumour and treatment characteristics,
suggesting that eSTS may have a more aggressive
tumour behaviour in elderly patients when compared
with their younger counterparts, which may coincide
with a weaker tumour-specific immune response in
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